Document:

Form of Third Amended and Restated Investor Rights Agreement

 Exhibit 4.3.2 
  
 JAZZ PHARMACEUTICALS, INC. 
 THIRD AMENDED AND RESTATED 
 INVESTOR RIGHTS AGREEMENT 

 JAZZ PHARMACEUTICALS, INC. 
 THIRD AMENDED AND RESTATED 
 INVESTOR
RIGHTS AGREEMENT 
 THIS THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is made effective
as of the Effective Date (as defined below), by and among Jazz Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the holders of Common Stock, Preferred Stock and/or warrants to purchase the Series BB
Preferred Stock of the Company listed on Exhibit A hereto (collectively, the “Investors”). 
 RECITALS

 WHEREAS, the Company and the Investors are parties to that certain Second Amended and Restated Investor Rights
Agreement, dated as of June 24, 2005 (the “Prior Agreement”); 
 WHEREAS, the Company and
the Investors who have executed this Agreement (for and on behalf of all Investors) wish to amend and restate the Prior Agreement in its entirety as set forth below; and 
 WHEREAS, Investors who are holders of at least 60% of the Registrable Securities held by all Investors, together with Managers holding a majority of the Registrable Securities held by all
Managers and the Company, have the right, pursuant to Section 19.5 of the Prior Agreement, to amend and restate the Prior Agreement in its entirety as set forth below. 
 NOW, THEREFORE, in consideration of the mutual agreements, covenants and considerations contained herein, the
Company and the Investors who have executed this Agreement (for and on behalf of all Investors) hereby agree to amend and restate the Prior Agreement in its entirety as follows: 
 1. Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 
 1.1 “Affiliate” shall mean, with respect to any Person, a Person directly or indirectly controlling, controlled by, or under
common control with, such Person; provided, however, that, except for purposes of Section 11.2, no Series BB Holder shall be considered an Affiliate of any other Person except to the extent, and only to the extent, that such
Series BB Holder holds Convertible Securities (or shares of Common Stock issued upon conversion thereof) other than Series BB Preferred Stock (or shares of Common Stock issued upon conversion thereof). 
 1.2 “Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering the
Securities Act. 
 1.3 “Control” shall have the meaning given such term under Rule 405 of the Securities Act.

 1.4 “Convertible Securities” shall mean the shares of the Company’s Series A
Preferred Stock, Series B Preferred Stock, Series B Prime Preferred Stock (“Series B/P Preferred Stock”) and Series BB Preferred Stock held from time to time by the Investors and their permitted assigns. 
 1.5 “Effective Date” shall mean the date of the closing of the Initial Public Offering. 
 1.6 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 
 1.7 “Form S-1” shall mean Form S-1 issued by the Commission or any comparable or successor form or forms then in effect.

 1.8 “Form S-3” shall mean Form S-3 issued by the Commission or any comparable or successor form or forms then in
effect. 
 1.9 “Group” means two or more Persons acting together as a partnership, limited partnership, syndicate or
other group for the purpose of acquiring, holding or disposing of or voting securities of the Company. 
 1.10
“Holder” shall mean any holder of outstanding Registrable Securities which have not been sold to the public, but only if such holder is one of the Investors or an assignee or transferee of registration rights as permitted by
Section 11. 
 1.11 “Initial B/P Holder” shall mean a Person that holds any shares of Series B/P Preferred Stock
as of the date the first share of Series B/P Preferred Stock is issued. 
 1.12 “Initial Public Offering” shall mean
the Company’s first firm commitment underwritten public offering of its Common Stock registered under the Securities Act 
 1.13
“KKR” shall mean Kohlberg Kravis Roberts & Co. L.P. and its Affiliates. 
 1.14
“Managers” shall mean Samuel R. Saks, Bruce C. Cozadd, Robert M. Myers, Matthew K. Fust, Carol A. Gamble and Janne L.T. Wissel. 
 1.15 “Material Adverse Event” shall mean any change, event or effect that is materially adverse to the general affairs, business, operations, assets, prospects, condition (financial or
otherwise) or results of operations of the Company and its subsidiaries taken as a whole. 
 1.16 “Person” means an
individual, partnership, corporation, limited liability company, limited partnership, business trust, joint stock company, trust, unincorporated association, joint venture, governmental authority or other entity of whatever nature. 
 1.17 The term “Preferred Stock” shall mean the Series A Preferred Stock, Series B Preferred Stock, Series B/P Preferred Stock and
Series BB Preferred Stock of the Company. 
  

 3 

 1.18 The terms “Register”, “Registered”, and
“Registration” refer to a registration effected by preparing and filing a registration statement on Form S-1, S-2 or S-3 in compliance with the Securities Act (“Registration Statement”), and the
declaration or ordering of the effectiveness of such Registration Statement. 
 1.19 “Registrable Securities” shall
mean (i) any Common Stock now owned or hereafter acquired by a Manager, (ii) the Common Stock issued or issuable upon conversion of the Convertible Securities, and (iii) any Common Stock issued (or issuable upon conversion or exercise
of any warrant, right or other security which is issued) upon stock dividends, subdivisions, stock splits, recapitalization, merger or other distributions with respect to, or in exchange for, or in replacement of, such securities identified in
clauses (i) and (ii) and this clause (iii), provided, however, that no shares of Common Stock shall be deemed Registrable Securities for purposes of this Agreement to the extent that such shares of Common Stock (A) have
been sold to the public through a Registration Statement or pursuant to Rule 144; (B) have been sold, transferred or otherwise disposed by a person in a transaction in which its rights under this Agreement were not assigned; (C) are held
by a Holder or Investors whose rights to cause the Company to register securities pursuant to this Agreement have terminated in accordance with Section 6 of this Agreement. 
 1.20 “Registration Expenses” shall mean (a) all expenses incurred by the Company or its subsidiaries in complying with
Sections 3 or 4 of this Agreement, including, without limitation, all federal and state registration, qualification, and filing fees, printing expenses, fees and disbursements of counsel for the Company, blue sky fees and expenses, and the expense
of any regular or special audits incident to or required by any such registration, and (b) the expenses of one special counsel for all Holders (if different from counsel to the Company) up to $45,000 and one special counsel for all Managers (if
different from counsel to the Company) up to $45,000. 
 1.21 “Securities Act” shall mean the Securities Act of 1933,
as amended, or any similar federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 1.22 “Selling Expenses” shall mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities pursuant to this Agreement, and all fees and disbursements
of counsel to the Holders and the Managers that are not included in Registration Expenses. 
 1.23 “Series BB Holder”
means a holder of warrants issued under the Stock Purchase Agreement, dated January 27, 2004 between the Company and certain Investors (as the same may be amended from time to time in accordance with the terms thereof, the “Purchase
Agreement”) to purchase shares of the Company’s Series BB Preferred Stock (“Series BB Warrants”) or Series BB Preferred Stock (or shares of Common Stock issued upon conversion thereof). 
 1.24 “Special Registration Statement” shall mean (i) any registration statement relating to any employee benefit plan;
(ii) with respect to any corporate reorganization or transaction under Rule 145 of the Securities Act, any registration statement related to the 

  

 4 

 
issuance or resale of securities issued in such a transaction; (iii) any registration statement related to stock issued upon conversion of debt
securities; or (iv) any WKSI Shelf Registration Statement that the Company’s Board of Directors shall, in its sole discretion, designate as a “Special Registration Statement” for purposes of this Agreement. 
 1.25 “WKSI Shelf Registration Statement” shall mean a registration statement on Form S-3 under the Securities Act (or any
successor form to Form S-3) which registration statement shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act (or any successor or similar rule under the Securities Act adopted by the Commission).

 2. Confidentiality. Each Investor agrees that it will keep confidential and will not use (except in connection with the
evaluation or monitoring of its investment or its representative’s service on the Board of Directors of the Company), disclose or divulge for a period of three years after receipt of any information regarding the Company and its business which
such Investor obtained from the Company pursuant to Section 2 of the Prior Agreement, and which the Company has marked or otherwise specifically identified to the Investor as being confidential either orally or in writing, unless such
information is known, or until such information becomes known, to the public through no fault of such Investor or its agents, or unless the Board of Directors, Chief Executive Officer, President or General Counsel of the Company gives his or her
written consent to the Investor’s release of such information, except that no such written consent shall be required (and the Investor shall be free to release such information) if such information is to be provided to the Investor’s
counsel or accountant, or to an officer, director, general partner, limited partner, stockholder, investment counselor or advisor of an Investor or such Investor’s Affiliate, or employee of an Investor or such Investor’s Affiliate with a
need to know such information; provided that any such counsel, accountant, officer, director, general partner, limited partner, stockholder, investment counselor or advisor, or employee is subject to confidentiality obligations no less restrictive
in any material respects than the provisions of this Section 2. Notwithstanding the foregoing, this Section 2 shall not apply (a) to information which an Investor learns from a third party with the right to make such disclosure,
provided such Investor complies with the restrictions imposed by the third party, (b) to information which is in an Investor’s possession prior to the time of disclosure by the Company and not acquired by such Investor under a
confidentiality obligation, (c) to the extent (after requesting and pursuing confidential treatment to the extent reasonably possible) an Investor is required to disclose such information by law or a governmental regulatory authority,
(d) to the extent (after requesting and pursuing confidential treatment to the extent reasonably possible) an Investor is required to disclose such information by court order, (e) to general and summary information disclosed to an
Investor’s or such Investor’s Affiliates’ general partners, limited partners, members, and/or stockholders in such Investor’s or such Affiliates’ periodic reporting to such parties or to an Investor’s or such
Investor’s Affiliates’ prospective investors in such Investor’s or such Affiliates’ marketing activities, in a manner consistent with the custom and practice of the private venture capital and/or private equity industries,
provided that such Investor or such Affiliate advise such parties that the information disclosed is confidential, and provided further that the information disclosed does not include any proprietary information of the Company, and (f) to an
Investor’s disclosure of the fact that such Investor has made an investment in the Company, the amount and general nature thereof, the identity of such Investor’s co-investors in the Company if previously disclosed by the Company or such
co-investor, and to such Investor’s disclosure of the general business and goals of the Company. 
  

 5 

 3. Demand Registrations. 
 3.1 Requests for Registration on Form Other Than Form S-3. 
 (a) Subject to the terms of this Agreement, in the event that the Company shall receive from a Holder or Holders (not including any Managers) of at least 40% of the Registrable Securities (or a lesser percentage of
such shares if the anticipated aggregate price to the public of such shares, net of Selling Expenses, would not be less than $25,000,000) at any time after six months after the effective date of the Registration Statement with respect to the Initial
Public Offering, a notice requesting that the Company effect any Registration with respect to at least 20% of the then outstanding shares of Registrable Securities (or a lesser percentage of such shares if the anticipated aggregate price to the
public of such shares, net of Selling Expenses, would not be less than $25,000,000) on a form other than Form S-3, the Company shall (i) promptly give notice of the proposed Registration to all other Holders and (ii) as soon as
practicable, and in any event, within 90 days from receipt of notice from the Holders requesting Registration, use reasonable best efforts to effect Registration of the Registrable Securities specified in such request, together with any Registrable
Securities of any Holder joining in such request as are specified in a notice given within 20 days after notice from the Company. So long as the Company is a registrant qualified to use Form S-3, the Company shall not be obligated to take any action
to effect any such registration pursuant to this Section 3.1(a) after the Company has effected one such Registration pursuant to this Section 3.1(a) and such Registration has been declared effective; provided, however, that
the demand registration under this Section 3.1(a) shall be in addition to the demand registration provided for under Section 3.1(b). 
 (b) Subject to the terms of this Agreement, in the event that the Company shall receive from a Holder who originally committed to purchase (and did not default in any purchase) at least 50,000,000 shares of Series B Preferred Stock and/or
Series B/P Preferred Stock (appropriately adjusted for combinations, consolidations, subdivisions, recapitalizations, stock splits and the like with respect to such shares) at any time after six months after the effective date of the Registration
Statement with respect to the Initial Public Offering, a notice requesting that the Company effect any Registration with respect to at least 20% of the then outstanding shares of Registrable Securities (or a lesser percentage of such shares if the
anticipated aggregate price to the public of such shares, net of Selling Expenses, would not be less than $25,000,000) on a form other than Form S-3, the Company shall (i) promptly give notice of the proposed Registration to all other Holders
and (ii) as soon as practicable, and in any event, within 90 days from receipt of notice from the Holder requesting Registration, use reasonable best efforts to effect Registration of the Registrable Securities specified in such request,
together with any Registrable Securities of any Holder joining in such request as are specified in a notice given within 20 days after notice from the Company. So long as the Company is a registrant qualified to use Form S-3, the Company shall not
be obligated to take any action to effect any such registration pursuant to this Section 3.1(b) after the Company has effected one such Registration pursuant to this Section 3.1(b) and such Registration has been declared effective;
provided, however, that the demand registration under this Section 3.1(b) shall be in addition to the demand registration provided for under Section 3.1(a). 
  

 6 

 (c) Notwithstanding anything to the contrary in Sections 3.1(a) and 3.1(b), the right of Managers to
participate in demand registrations shall be limited as follows: No Manager may sell a number of shares in a registered offering under Section 3.1(a) or 3.1(b) that exceeds X; where X equals the number of Registrable Securities held by such
Manager times the greater of Y or Z; Y equals the number of shares requested to be sold by KKR divided by the total number of shares of Registrable Securities held by KKR; and Z equals the number of shares requested to be sold by all Holders (other
than Managers) divided by the total number of shares of Registrable Securities (including for this purpose shares that would be Registrable Securities but for clause (B) of Section 1.17) held by such Holders (other than Managers). This
paragraph (c) shall terminate and be of no force and effect from such time, if any, as KKR ceases to own either Convertible Securities or Registrable Securities. 
 3.2 Request for Registration on Form S-3. 
 (a) If a Holder or Holders (not including any
Managers) of at least 20% of the outstanding shares of Registrable Securities requests that the Company file a Registration Statement on Form S-3 for an offering of shares of Registrable Securities, the anticipated aggregate price to the public of
which, net of Selling Expenses, would not be less than $25,000,000, and the Company is a registrant qualified to use Form S-3, the Company shall (i) promptly give notice of the proposed Registration to all other Holders and (ii) as soon as
practicable, use reasonable best efforts to effect a Registration of the Registrable Securities on such form, together with the Registrable Securities of any Holder joining in such request as are specified in a notice given within 20 days after
notice from the Company; provided, however, that the Company shall not be required to effect more than two Registrations pursuant to Section 3.2 in any 12 month period. All of the provisions of Section 3.5 shall be applicable
to each Registration initiated under this Section 3.2. 
 (b) For each $40,000,000 in original issue price of Registrable Securities
purchased by a Holder (a “Principal Holder”), such Principal Holder may request that the Company file a Registration Statement on Form S-3 for an offering of shares of Registrable Securities, and provided that the anticipated
aggregate price to the public of such shares, net of Selling Expenses, would not be less than $25,000,000 and the Company is a registrant qualified to use Form S-3, the Company shall (i) promptly give notice of the proposed Registration to all
other Holders and (ii) as soon as practicable, use reasonable best efforts to effect a Registration of the Registrable Securities on such form, together with the Registrable Securities of any Holder joining in such request as are specified in a
notice given within 20 days after notice from the Company; provided, however, that the Company shall not be required to effect more than two Registrations pursuant to Section 3.2 in any 12 month period. A Principal Holder shall
have the right to demand one Registration under this Section 3.2(b) for each $40,000,000 in original issue price of Registrable Securities purchased by such Holder. All of the provisions of Section 3.5 shall be applicable to each
Registration initiated under this Section 3.2. 
 (c) Notwithstanding anything to the contrary in Sections 3.2(a) and 3.2(b), the right
of Managers to participate in demand registrations shall be limited as follows: No Manager may sell a number of shares in a registered offering under Section 3.2(a) or 3.2(b) that exceeds X; where X equals the number of Registrable Securities
held by such Manager times the greater of Y or Z; Y equals the number of shares requested to be sold by KKR divided by the 

  

 7 

 
total number of shares of Registrable Securities held by KKR; and Z equals the number of shares requested to be sold by all Holders (other than Managers)
divided by the total number of shares of Registrable Securities (including for this purpose shares that would be Registrable Securities but for clause (B) of Section 1.17) held by all Holders (other than Managers). This paragraph
(c) shall terminate and be of no force and effect from such time, if any, as KKR ceases to own Convertible Securities or Registrable Securities. 
 3.3 Right of Deferral. 
 (a) Notwithstanding the foregoing, the Company shall not be obligated
to file a Registration Statement pursuant to Section 3: 
 (i) if the Company, within ten days of the receipt of the request from
Holders, gives notice of its bona fide intention to effect the filing of a Registration Statement with the Commission subject to Section 4 hereof within 60 days of receipt of such request (other than to a Registration of securities in a Rule
145 transaction or with respect to an employee benefit plan), provided that the Company is actively employing all reasonable best efforts to cause such Registration Statement to become effective; 
 (ii) within 120 days immediately following the effective date of any Registration Statement pertaining to the securities of the Company (other than
a registration of securities in a Rule 145 transaction or with respect to an employee benefit plan); or 
 (b) Notwithstanding the
foregoing, the Company shall not be obligated to file a Registration Statement pursuant to Section 3 if the Company shall furnish to the requesting Holders a certificate signed by the Chief Executive Officer of the Company stating that in the
good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its stockholders for a Registration Statement to be filed in the near future, then the Company’s obligation to use all reasonable best efforts to
file a Registration Statement shall be deferred for a period not to exceed 120 days from the receipt of the request to file such registration by such Holders; provided, however, that the Company shall not exercise the deferral rights
contained in these Sections 3.3(a)(i) and 3.3(b) more than once in any 12-month period. 
 3.4 Registration of Other Securities in
Demand Registration. Any Registration Statement filed pursuant to the request of the Holders under this Section 3 may, subject to the provisions of Section 3.5, include securities of the Company other than Registrable Securities.

 3.5 Underwriting in Demand Registration. 
 (a) Notice of Underwriting. If the Holders intend to distribute the Registrable Securities covered by their request made pursuant to this Section 3 by means of an underwriting, they shall so advise
the Company as a part of their request, and the Company shall include such information in the notice referred to in Sections 3.1 and 3.2. The right of any Holder to Registration pursuant to Section 3 shall be conditioned upon such Holder’s
agreement to participate in such underwriting and the inclusion of such Holder’s eligible Registrable Securities in the underwriting. 
  

 8 

 (b) Selection of Underwriter in Demand Registration. If a Registration requested pursuant
to Section 3.1 or 3.2 is to be underwritten, the Company shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement and related agreements with the representative
(“Underwriter’s Representative”) of the underwriter or underwriters selected for such underwriting by the Holders of a majority of the Registrable Securities being registered by the Holders and reasonably acceptable to
the Company. 
 (c) Marketing Limitation in Demand Registration. If the Underwriter’s Representative advises the Holders
in writing that market factors (including, without limitation, the aggregate number of shares of Common Stock requested to be Registered, the general condition of the market, and the status of the persons proposing to sell securities pursuant to the
Registration) require a limitation of the number of shares to be underwritten, then the number of shares of Registrable Securities that may be included in the Registration and underwriting shall be allocated among all Holders in proportion, as
nearly as practicable, to the respective amounts of Registrable Securities held by such Holders at the time of filing the Registration Statement. No Registrable Securities or other securities excluded from the underwriting by reason of this
Section 3.5(c) shall be included in such Registration Statement. 
 (d) Right of Withdrawal in Demand Registration. If
any Holder of Registrable Securities disapproves of the terms of the underwriting, such person may elect to withdraw therefrom by notice to the Company, the Underwriter’s Representative and the Holders requesting Registration delivered at least
ten days prior to the effective date of the Registration Statement. The securities so withdrawn shall also be withdrawn from the Registration Statement. 
 4. Piggyback Registration. 
 4.1 Notice of Piggyback Registration and Inclusion of
Registrable Securities; Special Limitation for Managers. 
 (a) Subject to the terms of this Agreement, if the Company
decides to Register any of its Common Stock on a form that would be suitable for a registration of Registrable Securities, other than a Special Registration Statement, whether pursuant to a demand registration contemplated by this Agreement or
otherwise, the Company will: (i) promptly give each Holder notice thereof (which shall include a list of the jurisdictions in which the Company intends to attempt to qualify such securities under the applicable Blue Sky or other state
securities laws) and (ii) subject to Section 4.2, include in such Registration (and any related qualification under Blue Sky laws or other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a
notice delivered to the Company by any Holder within 20 days after delivery of such notice from the Company. 
 (b) Notwithstanding anything
to the contrary in Section 4.1(a), the right of Managers to participate in demand registrations shall be limited as follows: No Manager may sell a number of shares in a registered offering under Section 4.1 that exceeds X; where X equals
the number of Registrable Securities held by such Manager times the greater of Y or Z; Y equals the number of shares requested to be sold by KKR divided by the total number of shares of 

  

 9 

 
Registrable Securities held by KKR; and Z equals the number of shares requested to be sold by all Holders (other than Managers) divided by the total number
of shares of Registrable Securities (including for this purpose shares that would be Registrable Securities but for clause (B) of Section 1.17) held by all Holders (other than the Managers). This paragraph (b) shall terminate and be
of no force and effect from such time, if any, as KKR ceases to own Convertible Securities or Registrable Securities. 
 4.2
Underwriting in Piggyback Registration. 
 (a) Notice of Underwriting in Piggyback Registration. If the
Registration of which the Company gives notice is for a Registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the notice given pursuant to Section 4.1. In such event, the right of any Holder
to Registration shall be conditioned upon such underwriting and the inclusion of such Registrable Securities in such underwriting to the extent provided in this Section 4. All Holders proposing to distribute their securities through such
underwriting shall (together with the Company) enter into an underwriting agreement and related agreements with the Underwriter’s Representative for such offering. The Holders shall have no right to participate in the selection of the
underwriters for an offering pursuant to this Section 4. 
 (b) Marketing Limitation in Piggyback Registration. If the
Underwriter’s Representative advises the Holders seeking registration of Registrable Securities pursuant to this Section 4 in writing that market factors (including, without limitation, the aggregate number of shares of Common Stock
requested to be Registered, the general condition of the market, and the status of the persons proposing to sell securities pursuant to the Registration) require a limitation of the number of shares to be underwritten, the Underwriter’s
Representative (subject to the allocation priority set forth in Section 4.2(c)) may: 
 (i) in the case of the Initial Public Offering,
exclude some or all of the Registrable Securities from such registration and underwriting; and 
 (ii) in the case of any Registered public
offering subsequent to the Initial Public Offering, limit the number of shares of Registrable Securities to be included in such Registration and underwriting to not less than 30% of the securities included in such Registration. 
 (c) Allocation of Shares in Piggyback Registration. If the Underwriter’s Representative limits the number of shares to be included in
a Registration pursuant to Section 4.2(b), the number of shares to be included in such Registration shall be allocated among all Holders, in proportion, as nearly as practicable, to the respective amounts of Registrable Securities which such
Holders hold at the time of filing the Registration Statement. No Registrable Securities or other securities excluded from the underwriting by reason of this Section 4.2(c) shall be included in the Registration Statement. 
 (d) Withdrawal in Piggyback Registration. If any Holder disapproves of the terms of any such underwriting, such person may elect to
withdraw therefrom by notice to the Company and the Underwriter’s Representative delivered at least ten days prior to the effective date of the Registration Statement. Any Registrable Securities or other securities excluded or withdrawn from
such underwriting shall be withdrawn from such Registration. 
  

 10 

 5. Expenses of Registration.All Registration Expenses incurred in connection with
Registrations pursuant to Section 3.1, 3.2 and 4, shall be borne by the Company. All Registration Expenses incurred in connection with any other Registration, qualification, or compliance, shall be apportioned among the Company and the Holders
of the securities so registered on the basis of the number of shares so registered. Notwithstanding the above, the Company shall not be required to pay for any expenses of any Registration proceeding begun pursuant to Section 3 if the
Registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (which Holders shall bear such expenses), unless the Holders of a majority of the Registrable Securities agree
to forfeit their right to one Registration pursuant to Section 3; provided, however, that if at the time of such withdrawal, the Holders have learned of a Material Adverse Event not known to the Holders at the time of their
request, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 3. All Selling Expenses shall be borne by the holders of the securities Registered pro rata on the basis of the number
of shares Registered. 
 6. Termination of Registration Rights. The rights to cause the Company to register securities granted
under Sections 3 and 4 of this Agreement and to receive notices pursuant to Section 4 of this Agreement shall terminate, with respect to each Holder, on the earlier of (i) the twelfth anniversary of the date that the first share of Series
B Preferred Stock is sold and issued by the Company, and (ii) with respect to each Holder if such Holder is eligible to sell all of such Holder’s Registrable Securities under Rule 144 of the Securities Act (excluding Rule 144(k)
thereunder) within any three month period without volume limitations. 
 7. Registration Procedures and Obligations. Whenever
required under this Agreement to effect any Registration of securities, the Company shall, as expeditiously as reasonably possible: 
 (a)
Prepare and file with the Commission a Registration Statement with respect to such securities and use its reasonable best efforts to cause such Registration Statement to become effective, and, in the case of a Registration pursuant to Section 3
or Section 4, upon the request of the sellers of a majority of the Registrable Securities registered thereunder, keep such Registration Statement effective for up to two years. 
 (b) Furnish to each seller of Registrable Securities a copy of any information contained in the Registration Statement about such seller for the purpose
of allowing the seller to verify the information. 
 (c) Prepare and file as expeditiously as reasonably practicable with the Commission
such amendments and supplements to such Registration Statement and the prospectus used in connection with such Registration Statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all
securities covered by such Registration Statement. 
  

 11 

 (d) Furnish to the sellers of Registrable Securities such numbers of copies of a prospectus, including a
preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 
 (e) Use its reasonable best efforts to register and qualify the Registrable Securities covered by such Registration Statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the sellers of Registrable Securities, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business
in any jurisdiction where it is not so qualified or to file a general consent to service of process in any such states or jurisdictions, and provided further that in the event any jurisdiction in which the securities shall be qualified imposes a
non-waivable requirement that expenses incurred in connection with the qualification of the securities be borne by selling stockholders, such expenses shall be payable pro rata by selling stockholders. 
 (f) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement and related agreements, in
usual and customary form, with the managing underwriter of such offering. Each seller of Registrable Securities participating in such underwriting shall also enter into and perform its obligations under such an agreement and related agreements.

 (g) Promptly notify each seller of Registrable Securities covered by such Registration Statement at any time when a prospectus relating
thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 
 (h) Provide a transfer agent and registrar for all securities registered pursuant to such Registration Statement and a CUSIP number for all such securities, in each case not later than the effective date of such
registration. 
 (i) Furnish, at the request of any Holder requesting Registration of Registrable Securities pursuant to this Agreement, on
the date that such Registrable Securities are delivered for sale in connection with a Registration pursuant to this Agreement, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such Registration, in
form and substance as is customarily given to underwriters (with an information copy provided to each Holder selling Registrable Securities) in an underwritten public offering, and (ii) a letter dated such date, from the independent certified
public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters (with an information copy provided to each
holder of Registrable Securities). 
 (j) Use all reasonable best efforts to list the securities covered by such Registration Statement with
NASDAQ or any securities exchange on which the Common Stock of the Company is then listed, or NASDAQ or such securities exchange as shall be selected by the Company. 
  

 12 

 (k) Notify each seller of Registrable Securities under such Registration Statement of (i) the
effectiveness of such Registration Statement, (ii) the filing of any post-effective amendments to such Registration Statement, or (iii) the filing of a supplement to such Registration Statement. 
 (l) Make available for inspection upon reasonable notice during the Company’s regular business hours by each seller of Registrable Securities, any
underwriter participating in any distribution pursuant to such Registration Statement, and any attorney, accountant or other agent retained by such seller or underwriter, all material financial and other records, pertinent corporate documents and
properties of the Company, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such Registration Statement.
Each seller of Registrable Securities agrees to use the same degree of care as such seller uses to protect its own confidential information, but in no event less than reasonable care, to keep confidential any information furnished to it by the
Company pursuant to this Subsection 7(l) for a period of 3 years (so long as such information is not in the public domain); provided, however, such seller’s obligation to keep information confidential under this Subsection 7(l)
shall not apply (a) to information which such seller learns from a third party with the right to make such disclosure, provided the seller complies with the restrictions imposed by the third party, (b) to information which is in
seller’s possession prior to the time of disclosure by the Company and not acquired by seller under a confidentiality obligation, (c) to the extent (after requesting and pursuing confidential treatment to the extent reasonably possible)
the seller is required to disclose such information by law or a governmental regulatory authority, (d) to the extent (after requesting and pursuing confidential treatment to the extent reasonably possible) seller is required to disclose such
information by court order, and (e) to information disclosed to any partner, subsidiary, parent, legal counsel or advisor of such seller for the purpose of evaluating or monitoring its investment in the Company. Notwithstanding anything
herein to the contrary, any party to this Agreement (and any employee, representative, or other agent of any party to this Agreement) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the
transactions contemplated by this Agreement and all materials of any kind (including opinions or other tax analyses) that are provided to it relating to such tax treatment and tax structure. 
 (m) Cause the senior executive officers of the Company to participate in the customary “road show” presentations that may be reasonably
requested by the Holders or the managing underwriter in any underwritten offering and otherwise to facilitate, cooperate with, and participate in each underwritten offering. 
 (n) Cooperate with each seller of Registrable Securities and each underwriter or agent, if any, participating in the disposition of such Registrable
Securities and their respective counsel in connection with any filings required to be made with the National Association of Securities Dealers, Inc. 
 8. Information Furnished by Holder. It shall be a condition precedent of the Company’s obligations under Sections 3 and 4 of this Agreement that each Holder holding Registrable Securities included
in any Registration furnish to the Company such information regarding such Holder and the distribution proposed by such Holder(s) as the Company may reasonably request. 
  

 13 

 9. Indemnification. 
 9.1 Company’s Indemnification of Holders. To the extent permitted by law, the Company will indemnify and hold harmless each Holder,
each of its officers, directors, and constituent partners and members, legal counsel for the Holders, and each person controlling such Holder, with respect to which Registration, qualification, or compliance of Registrable Securities has been
effected pursuant to this Agreement, and each underwriter, if any, and each person who controls any underwriter against all claims, losses, damages, liabilities, or actions in respect thereof (collectively, “Damages”) to the
extent such Damages arise out of or are based upon any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus or other document (including any related Registration Statement) incident to any such Registration,
qualification, or compliance, or are based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by the Company of any rule
or regulation promulgated under the Securities Act applicable to the Company and relating to action or inaction required of the Company in connection with any such Registration, qualification, or compliance; and the Company will reimburse each such
Holder, each such underwriter, and each person who controls any such Holder or underwriter, for any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action;
provided, however, that the indemnity contained in this Section 9.1 shall not apply to amounts paid in settlement of any such Damages if settlement is effected without the consent of the Company (which consent shall not
unreasonably be withheld or delayed); and provided, further, that the Company will not be liable (i) in any such case to the extent that any such Damages arise out of or are based upon any untrue statement or omission based upon written
information furnished to the Company by such Holder, underwriter, or controlling person and stated to be for use in connection with the offering of securities of the Company or (ii) in the case of a sale directly by a Holder of Registrable
Securities (including a sale of such Registrable Securities through any underwriter retained by such Holder engaging in a distribution solely on behalf of such Holder), if such untrue statement or alleged untrue statement or omission or alleged
omission was contained in a preliminary prospectus and corrected in a final or amended prospectus, and such Holder failed to deliver a copy of the final or amended prospectus at or prior to the confirmation of the sale of the Registrable Securities
to the person asserting any such loss, claim, damage, liability or action in any case in which such delivery is required by the Securities Act. 
 9.2 Holder’s Indemnification of Company. To the extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such Registration, qualification or,
compliance is being effected pursuant to this Agreement, indemnify and hold harmless the Company, each of its directors and officers, each legal counsel and independent accountant of the Company, each underwriter, if any, of the Company’s
securities covered by such a Registration Statement, each person who controls the Company or such underwriter within the meaning of the Securities Act, and each other seller of Registrable Securities and each of its officers, directors, and
constituent partners, and each person controlling such other seller, against all Damages arising out of or based upon any untrue 

  

 14 

 
statement (or alleged untrue statement) of a material fact contained in any such Registration Statement, prospectus, offering circular, or other document, or
any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by such Holder of any rule or regulation promulgated under the Securities
Act applicable to such Holder and relating to action or inaction required of such Holder in connection with any such Registration, qualification, or compliance, and will reimburse the Company, such other sellers of Registrable Securities, such
directors, officers, partners, persons, law and accounting firms, underwriters or control persons for any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or
action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such Registration Statement, prospectus, offering circular, or other document in
reliance upon and in conformity with written information furnished to the Company by such Holder and stated to be specifically for use in connection with the offering of securities of the Company, provided, however, that the indemnity
contained in this Section 9.2 shall not apply to amounts paid in settlement of any such Damages if settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld or delayed); and provided, further,
that each Holder’s liability under this Section 9.2 shall not exceed such Holder’s net proceeds from the offering of securities made in connection with such Registration. 
 9.3 Indemnification Procedure. Promptly after receipt by an indemnified party under this Section 9 of notice of the commencement of
any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section 9, notify the indemnifying party in writing of the commencement thereof and generally summarize such action.
The indemnifying party shall have the right to participate in and to assume the defense of such claim; provided, however, that the indemnifying party shall be entitled to select counsel for the defense of such claim with the approval
of any parties entitled to indemnification, which approval shall not be unreasonably withheld or delayed; provided further, however, that if either party reasonably determines that there may be a conflict between the position of the
Company and the Investors in conducting the defense of such action, suit, or proceeding by reason of recognized claims for indemnity under this Section 9, then counsel for such party shall be entitled to conduct the defense to the extent
reasonably determined by such counsel to be necessary to protect the interest of such party. The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to the ability of the indemnifying party to
defend such action, shall relieve such indemnifying party, to the extent so prejudiced, of any liability to the indemnified party under this Section 9, but the omission so to notify the indemnifying party will not relieve such party of any
liability that such party may have to any indemnified party otherwise than under this Section 9. 
 9.4 Contribution. If
the indemnification provided for in this Section 9 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any Damages referred to therein, then the indemnifying party, in lieu of indemnifying such
indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such Damages in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the
indemnified party on the other in connection with the statements or omissions that resulted in such Damages as well as any other relevant equitable considerations; provided, however, that in no event shall any contribution by a 

  

 15 

 
Holder under this Section 9.4 exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. The
relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. 
 9.5 Conflicts. Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the
underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
 9.6 Survival of Obligations. The obligations of the Company and Holders under this Section 9 shall survive the completion of any
offering of Registrable Securities in a Registration Statement under this Agreement or otherwise. 
 10. Limitations on Registration
Rights Granted to Other Securities. From and after the date of this Agreement, so long as at least 10,000,000 shares of the Convertible Securities (including shares of Common Stock issued upon conversion thereof and as adjusted for
combinations, consolidations, subdivisions, stock splits and the like with respect to such shares) remain issued and outstanding, the Company shall not enter into any agreement with any holder or prospective holder of any securities of the Company
providing for the granting to such holder of any Registration rights, except that, with the consent of the Holders holding at least 55% of the Registrable Securities then held by the Holders, additional persons may be added as parties to this
Agreement with regard to any or all securities of the Company held by them. Any such additional parties shall execute a counterpart of this Agreement, and upon execution by such additional parties and by the Company, shall be considered a Holder for
all purposes of this Agreement and any Common Stock held by them or issued or issuable upon conversion of any securities held by them, and any Common Stock issued (or issuable upon conversion or exercise of any warrant, right or other security which
is issued) upon stock dividends, subdivisions, stock splits, recapitalization, merger or other distributions with respect to, or in exchange for, or in replacement of, such securities identified in this clause, excluding, however, any securities
previously sold to the public and any securities sold by a person in a transaction in which its rights under this Agreement are not assigned, shall be considered Registrable Securities. The additional parties and the additional Registrable
Securities shall be identified in an amendment to Exhibit A hereto. 
 11. Transferability. 
 11.1 Limitations on Transferability. Each Investor covenants that in no event will it dispose of any of the Convertible Securities or
Registrable Securities (other than pursuant to Rule 144 promulgated by Commission under the Securities Act (“Rule 144”) or other exemption from registration, or except in connection with an Investor’s exercise
of its Registration rights under this Agreement) unless and until (a) the Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a statement of the circumstances surrounding the proposed
disposition, and (b) if reasonably requested by the 

  

 16 

 
Company, the Investor shall have furnished the Company with an opinion of counsel reasonably satisfactory in form and substance to the Company and the
Company’s counsel to the effect that (x) such disposition will not require registration under the Securities Act and (y) appropriate action necessary for compliance with the Securities Act and any applicable state, local, or foreign
law has been taken. Notwithstanding the limitations set forth in the foregoing sentence, if the Investor is a partnership or limited liability company it may transfer the Convertible Securities or Registrable Securities to its constituent partners
or members or its Affiliates, or a retired partner or member of such partnership or limited liability company who retires after the date hereof, or to the estate of any such partner or member or retired partner or retired member or transfer by gift,
will, or intestate succession to any such partner’s or member’s spouse, domestic partner, lineal descendants or ancestors without the necessity of registration or opinion of counsel if the transferee agrees in writing to be subject to the
terms of the Transactional Agreements, as applicable, to the same extent if such transferee were an Investor; provided, however, that Investor hereby covenants not to effect such transfer if such transfer either would invalidate the
securities laws exemptions pursuant to which the Convertible Securities or Registrable Securities were originally offered and sold or would itself require registration and/or qualification under the Securities Act or applicable state securities
laws. Notwithstanding the foregoing, an Investor who is a Manager shall not dispose of any Convertible Securities or Registrable Securities in contravention of the Transactional Agreements (as defined herein). Each certificate evidencing the
Convertible Securities or Registrable Securities transferred as provided above shall bear the appropriate restrictive legend set forth in Section 5.1 of the Purchase Agreement, except that such certificate shall not bear such legend if the
transfer was made in compliance with Rule 144 or if the opinion of counsel referred to above is to the further effect that such legend is not required in order to establish compliance with any provisions of the Securities Act. 
 11.2 Transfer of Rights. The right to cause the Company to Register securities granted by the Company to the Holders under Sections 3 and 4
of this Agreement may be assigned by any Investor or its Affiliates to a transferee or assignee of any Convertible Securities or Registrable Securities not sold to the public acquiring the lesser of (a) at least 50% of the Registrable
Securities and Convertible Securities then held by such Investor or its Affiliates with respect to the first transfer by such Investor or its Affiliates to a non-Affiliate, 100% of the Registrable Securities and Convertible Securities then held by
such Investor or its Affiliates with respect to any subsequent transfer by such Investor or its Affiliates to a non-Affiliate, or 100% of the Registrable Securities and Convertible Securities held by a transferee or assignee of a Holder to a
non-Affiliate of such transferee or assignee, and (b) at least 2,000,000 shares (or such lesser number of shares as would be held by an Investor who has a Total Capital Commitment of $2,727,200 as defined in the Purchase Agreement, and who has
not sold any shares acquired under the Purchase Agreement) of the Convertible Securities or Registrable Securities (as adjusted for combinations, consolidations, subdivisions, stock splits and the like with respect to such shares) to a
non-Affiliate; provided, however, that (i) the Company must receive notice prior to the time of said transfer, stating the name and address of said transferee or assignee and identifying the securities with respect to which such
rights are being assigned, (ii) the Board of Directors must consent to the assignment, which consent shall not be unreasonably withheld, and (iii) such transferee or assignee must agree in writing to be bound by the terms and conditions of
this Agreement. Notwithstanding the limitation set forth in the foregoing sentence respecting the minimum number of shares which must be transferred, any Holder which is a corporation, partnership or limited liability company may transfer such
Holder’s Registration rights under Sections 3 and 4 to such Holder’s Affiliates, as the case may be, without restriction as to the number or percentage of shares acquired by any such Affiliates. 
  

 17 

 12. Market Standoff. Each Holder hereby agrees that, if so requested by the Company and the
Underwriter’s Representative (if any), such Holder shall not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise transfer or dispose of any Registrable Securities or other securities of the Company
(“Market Standoff”) without the prior written consent of the Company and the Underwriter’s Representative for such period of time (a) not to exceed 180 days following the effective date of a Registration Statement
of the Company filed under the Securities Act in the case of the Initial Public Offering or (b) commencing with the date the Company provides notice to the Holders of a proposed follow-on offering pursuant to Section 4.1 (including
Registrations initiated pursuant to Section 3) and ending 90 days after the effective date of the Registration Statement or, in the event of a shelf registration, the date of the prospectus for such follow-on offering, as may be requested by
the Underwriter’s Representative; provided, however, that a Holder shall not be required to agree to a Market Standoff for a period of time that commences less than 30 days after the expiration of another period of time during
which the Holder has agreed to a Market Standoff. The obligations of the Holders under this Section 12 shall be conditioned upon similar agreements being in effect with each other stockholder who is an officer, or director or, with respect only
to the Initial Public Offering, greater than 1% stockholder of the Company prior to such Initial Public Offering. 
 13. Conversion of
Preferred Stock. The Registration rights of the Holders of the Registrable Securities set forth in this Agreement are conditioned upon the conversion of the Registrable Securities with respect to which registration is sought into Common
Stock immediately prior to the closing of the offering of such Registrable Securities pursuant to an effective Registration Statement. 
 14.
Reports Under the Exchange Act. With a view to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the Commission that may at any time permit a Holder to
sell securities of the Company to the public without Registration or pursuant to a registration on Form S-3, the Company agrees, for as long as a Holder holds Registrable Securities, to: 
 (a) make and keep public information available, as those terms are understood and defined in Rule 144, at all times after the effective date of the first
Registration Statement filed by the Company for the offering of its securities to the public; 
 (b) take such action as is necessary to
enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first Registration Statement filed by the Company for the offering of
its securities to the general public is declared effective; 
 (c) file with the Commission in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act; 
 (d) furnish to any Holder, so long as the Holder owns
any Registrable Securities, promptly upon request (i) a written statement by the Company that it has complied 

  

 18 

 
with the reporting requirements of Rule 144 (at any time after 90 days after the effective date of the first Registration Statement filed by the Company),
the Securities Act, and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies),
(ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or
regulation of the Commission which permits the selling of any such securities without Registration or pursuant to such form; and 
 (e) at
any time, at the request of any Holder of Registrable Securities, make available to such Holder and to any prospective transferee of such Registrable Securities the information concerning the Company described in Rule 144A(d)(4) under the Securities
Act. 
 15. Miscellaneous. 
 15.1 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of California excluding those laws that direct the application of the laws of another jurisdiction. 

15.2 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
 15.3 Headings. The headings of the Sections of this Agreement
are for convenience and shall not by themselves determine the interpretation of this Agreement. 
 15.4 Notices. All notices
required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient,
or if not, then on the next business day; or (iii) one day after deposit with a nationally (or internationally) recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices to the Company shall
be sent to the Company’s principal place of business. All notices to other parties to this Agreement shall be sent to the address as set forth on the signature page or at such other address as such party may designate by ten days advance notice
to the other parties. 
 15.5 Amendment and Waiver of Agreement. Except as otherwise provided herein, any provision of this
Agreement may be amended or waived only by a written instrument signed by the Company and Holders holding at least 60% of the Registrable Securities then held by all Holders. Notwithstanding the foregoing, neither Subsections 3.1(b) or 3.2(b), or
this sentence of Section 15.5, may be amended or waived without the consent of all Holders who have demand rights under Subsections 3.1(b) and 3.2(b). In addition, this Agreement may not be amended to increase any material financial
obligations of any Investor hereunder without the prior written consent of such Investor. Any waiver, amendment, modification or termination of any provision of this Agreement shall be binding on all parties hereto and their respective successors
and permitted assigns. 
  

 19 

 15.6 Severability. In the event one or more of the provisions of this Agreement should, for
any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or
unenforceable provision had never been contained herein. 
 15.7 Entire Agreement; Successors and Assigns. This Agreement and
the Transactional Agreements (as defined below) constitute the entire agreement between the parties regarding the subject matter hereof and thereof and supersede and replace any and all prior negotiations, correspondence, understandings and
agreements, including without limitation the Prior Agreement, between the parties regarding the subject matter hereof and thereof. For purposes of this Agreement, the “Transactional Agreements” shall mean the Purchase
Agreement and the Second Amended and Restated Right of First Refusal and Co-Sale Agreement, each dated as of June 24, 2005, among the Company and other parties identified therein, the Second Amended and Restated Voting Agreement, dated as of
June 24, 2005, among the Company and the parties identified therein, and the Employment Agreements dated as of February 18, 2004 between the Company and each of the Executives named in Section 6.10 of the Purchase Agreement, each as
may be amended in accordance with its terms. Subject to the exceptions specifically set forth in this Agreement, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective executors, administrators,
heirs, successor, and permitted assigns of the parties. 
 15.8 Aggregation. All outstanding shares of capital stock of the
Company held or acquired by an Affiliate of a Person shall be aggregated together with all other shares of capital stock held by such Person for the purpose of determining the availability of any rights under this Agreement. 
 15.9 Cumulative Remedies. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other
right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not
prevent the concurrent assertion or employment of any other right or remedy. 
 15.10 Specific Performance. The parties hereto
hereby declare that it is impossible to measure in money the damages that will accrue to a party hereto or to their heirs, personal representatives, or assigns by reason of a failure to perform any of the obligations under this Agreement and agree
that the terms of this Agreement shall be specifically enforceable. If any party hereto or his heirs, personal representatives, or assigns institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom
such action or proceeding is brought hereby waives the claim or defense therein that such party or such personal representative has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that
such remedy at law exists. 
 15.11 Accession; Amendment of Exhibit. Any person that becomes an Investor as defined in the
Purchase Agreement or a registered holder of a Series BB Warrant shall become a party to this Agreement by executing and delivering to the Company a counterpart signature pages to this Agreement and shall thereupon be deemed an “Investor”
for all purposes of this 

  

 20 

 
Agreement. The number of shares of Convertible Securities, Registrable Securities owned by each Investor, and the number of shares (if any) of Series BB
Preferred Stock subject to Series BB Warrants held by each Investor, as of the date hereof is set forth on Exhibit A, which exhibit may be amended from time to time by the Company upon notice to the Investors to reflect changes in the number
of shares of Convertible Securities or Registrable Securities owned by the Investors; provided, however, that no such notice shall be required upon the exercise of the Series BB Warrants by any of the Investors; provided further,
however, that the failure to so amend Exhibit A shall have no effect on the rights of the Investors under this Agreement. 
 [SIGNATURE
PAGES FOLLOW] 
  

 21 

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
  

			
	COMPANY:
	
	JAZZ PHARMACEUTICALS, INC.
		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	 KKR JP LLC

		
	 Signature:
	 	  

	 Print Name:
	 	  

	 Title:
	 	  

	
	KKR JP III LLC
		
	 Signature:
	 	  

	 Print Name:
	 	  

	 Title:
	 	  

	
	KKR TRS HOLDINGS, INC.
		
	 Signature:
	 	  

	 Print Name:
	 	  

	 Title:
	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	PROSPECT VENTURE PARTNERS II, L.P.
	
	 By:   Prospect Management Co. II, LLC,
          its General Partner

		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	PROSPECT ASSOCIATES II, L.P.
	
	 By:   Prospect Management Co. II, LLC,
          its General Partner

		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	VERSANT VENTURE CAPITAL II, L.P.
	
	 By:   Versant Ventures II, L.L.C.,
          its General Partner

		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	VERSANT SIDE FUND II, L.P.
	
	 By:   Versant Ventures II, L.L.C.,
          its General Partner

		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	VERSANT AFFILIATES FUND II-A, L.P.
	
	 By:   Versant Ventures II, L.L.C.,
          its General Partner

		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	THOMA CRESSEY FUND VII, L.P.
		
	By:	 	TC Partners VII, L.P.
	Its:	 	General Partner
		
	By:	 	Thoma Cressey Bravo Inc.
	Its:	 	General Partner

			
		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	THOMA CRESSEY FRIENDS FUND VII, L.P.

			
		
	 By:
	 	TC Partners VII, L.P.
	 Its:
	 	General Partner
		
	 By:
	 	Thoma Cressey Bravo Inc.
	 Its:
	 	General Partner

			
		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	JAZZ INVESTORS, L.L.C.
	
	 By:   Beecken Petty & Company, LLC.,
          its Manager

		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	CCG INVESTMENT FUND, L.P.
		
	By:	 	Golden Gate Capital Management, L.L.C.
		 	Its: Authorized Representative

			
		
	By:	 	  

		 	Its: Managing Director

			
	
	CCG AV, LLC-SERIES C
		
	By:	 	Golden Gate Capital Management, L.L.C.
		 	Its: Authorized Representative

			
		
	By:	 	  

		 	Its: Managing Director

			
	
	CCG ASSOCIATES-QP, LLC
		
	By:	 	Golden Gate Capital Management, L.L.C.
		 	Authorized Representative

			
		
	By:	 	  

		 	Its: Managing Director

			
	
	CCG INVESTMENT FUND-AI, LP
		
	By:	 	Golden Gate Capital Management, L.L.C.
		 	Its: Authorized Representative

			
		
	By:	 	  

		 	Its: Managing Director

			
	
	CCG CI, LLC
		
	By:	 	Golden Gate Capital Management, L.L.C.
		 	Its: Authorized Representative

			
		
	By:	 	  

		 	Its: Managing Director

			
	
	CCG AV, LLC – SERIES A
		
	By:	 	Golden Gate Capital Management, L.L.C.
		 	Its: Authorized Representative

			
		
	By:	 	  

		 	Its: Managing Director

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

									
	LB I GROUP INC.	 		 	LEHMAN BROTHERS HEALTHCARE VENTURE CAPITAL L.P.
				
	 Signature:
	 	  
	 		 	 By:   Lehman Brothers HealthCare Venture Capital Associates L.P., its General Partner

	 Print Name:
	 	  
	 		 	 By:   LB I Group Inc., its General Partner

	 Title:
	 	  
	 		 		 	
		 		 		 	Signature:	 	  

		 		 		 	Print Name:	 	  

		 		 		 	Title:	 	  

				
		 		 		 	LEHMAN BROTHERS P.A. LLC
					
		 		 		 	Signature:	 	  

		 		 		 	Print Name:	 	  

		 		 		 	Title:	 	  

				
		 		 		 	LEHMAN BROTHERS PARTNERSHIP ACCOUNT 2000/2001, L.P.
				
		 		 		 	 By:   LB I Group Inc., its General Partner

					
		 		 		 	Signature:	 	  

		 		 		 	Print Name:	 	  

		 		 		 	Title:	 	  

				
		 		 		 	LEHMAN BROTHERS OFFSHORE PARTNERSHIP ACCOUNT 2000/2001, L.P.
				
		 		 		 	 By:   Lehman Brothers Offshore Partners Ltd., its General Partner

					
		 		 		 	Signature:	 	  

		 		 		 	Print Name:	 	  

		 		 		 	Title:	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	 BVCF IV, L.P.

	
	 By:   Adams Street Partners, LLC, its General Partner

		
	 Signature:
	 	  

	 Print Name:
	 	  

	 Title:
	 	  

	
	ADAMS STREET V, L.P.
	
	 By:   Adams Street Partners, LLC, its General Partner

		
	 Signature:
	 	  

	 Print Name:
	 	  

	 Title:
	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	EGS PRIVATE HEALTHCARE PARTNERSHIP II, L.P.
	
	 By:   EGS Private Healthcare Investments, L.L.C., its General Partner

		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	EGS PRIVATE HEALTHCARE INVESTORS II, L.P.
	
	 By:   EGS Private Healthcare Investments, L.L.C., its General Partner

		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	EGS PRIVATE HEALTHCARE CANADIAN PARTNERS, L.P.
	
	 By:   EGS Private Healthcare Investments, L.L.C., its General Partner

		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	EGS PRIVATE HEALTHCARE PRESIDENTS FUND, L.P.
	
	 By:   EGS Private Healthcare Investments, L.L.C., its General Partner

		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	CARDINAL FUND I, L.P.
	
	 By:   Cardinal Management I, L.P., General Partner

	 By:   Cardinal MGP, L.L.C., General Partner

		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

	
	FW JAZZ PHARMA INVESTORS, L.P.
	
	 By:   Group VI, 31, L.L.C., General Partner

		
	Signature:	 	  

	Print Name:	 	  

	Title:	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	WAUD CAPITAL PARTNERS, L.P.
	
	 By:   Waud Capital Partners, L.L.C.

	 Its:   General Partner

		
	 Signature:
	 	  

	 Print Name:
	 	  

	 Title:
	 	  

	
	WAUD CAPITAL AFFILIATES, L.L.C.
		
	 Signature:
	 	  

	 Print Name:
	 	  

	 Title:
	 	  

	
	DEEP COVE MEZZANINE, LLC
		
	 Signature:
	 	  

	 Print Name:
	 	  

	 Title:
	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

									
	LERNER ENTERPRISES, L.P.	 		 	OAK HILL CREDIT ALPHA FINANCE I (OFFSHORE), LTD.
				
	 By:   Oak Hill Advisors, L.P., as Investment Manager for Lerner Enterprises, L.P.
	 		 		 	
					
	 Signature:
	 	  
	 		 	 Signature:
	 	  

	 Print Name:
	 	  
	 		 	 Print Name:
	 	  

	 Title:
	 	  
	 		 	 Title:
	 	  

				
		 		 		 	OAK HILL CREDIT OPPORTUNITIES FINANCING, LTD.
					
		 		 		 	 Signature:
	 	  

		 		 		 	 Print Name:
	 	  

		 		 		 	 Title:
	 	  

				
		 		 		 	COAST DL FUNDING LLC
					
		 		 		 	 Signature:
	 	  

		 		 		 	 Print Name:
	 	  

		 		 		 	 Title:
	 	  

			
		 		 	OAK HILL CREDIT ALPHA FINANCE I, LLC
				
		 		 		 	 By:   Oak Hill Credit Alpha Fund, L.P., its Member

		 		 		 	 By:   Oak Hill Credit Alpha Gen Par, L.P.,
          its General Partner

		 		 		 	 By:   Oak Hill Credit Alpha MGP, LLC.,
          its General Partner

					
		 		 		 	 Signature:
	 	  

		 		 		 	 Print Name:
	 	  

		 		 		 	 Title:
	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

			
	GENERAL ELECTRIC PENSION TRUST
	
	 By:   GE Asset Management Incorporated
          Its Investment Manager

		
	 Signature:
	 	  

	 Print Name:
	 	  

	 Title:
	 	  

 IN WITNESS WHEREOF, the undersigned have executed
this THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT effective as of the Effective Date. 
 INVESTORS: 
  

	
	 
	SAMUEL R. SAKS
	
	 
	BRUCE C. COZADD
	
	 
	ROBERT M. MYERS
	
	 
	JANNE L.T. WISSEL
	
	 
	MATTHEW K. FUST
	
	 
	CAROL A. GAMBLE

 Exhibit A 
 SCHEDULE OF INVESTORS 
  

					
	 Name and Address
	 	 Securities
	 	 
			
	 KKR JP LLC
 9 W. 57th Street, 42nd
Floor
 New York, NY 10019
	 	8,577,974 shares of Series B/P Preferred Stock	 	
			
	 KKR JP III LLC
 9 W. 57th Street, 42nd Floor
 New York, NY 10019
	 	36,445 shares of Series B/P Preferred Stock	 	
			
	 Thoma Cressey Fund VII, L.P.
 Sears Tower, 92nd Floor
 233 South Wacker
Drive
 Chicago, IL 60606
	 	1,957,380 shares of Series B Preferred Stock	 	
			
	 Thoma Cressey Friends Fund VII, L.P.
 Sears Tower,
92nd Floor
 233 South
Wacker Drive
 Chicago, IL 60606
	 	30,562 shares of Series B Preferred Stock	 	
			
	 CCG Investment Fund, LP
 c/o Golden Gate
Capital
 One Embarcadero Center, 33rd Floor
 San Francisco, CA 94111
	 	860,336 shares of Series B Preferred Stock	 	
			
	 CCG AV, LLC-Series C
 c/o Golden Gate Capital

One Embarcadero Center, 33rd
Floor
 San Francisco, CA 94111
	 	43,461 shares of Series B Preferred Stock	 	
			
	 CCG Associates-QP, LLC
 c/o Golden Gate
Capital
 One Embarcadero Center, 33rd Floor
 San Francisco, CA 94111
	 	47,269 shares of Series B Preferred Stock	 	
			
	 CCG Investment Fund-AI, LP
 c/o Golden Gate
Capital
 One Embarcadero Center, 33rd Floor
 San Francisco, CA 94111
	 	11,525 shares of Series B Preferred Stock	 	

					
	 Name and Address
	 	 Securities
	 	 
	 CCG AV, LLC-Series A
 c/o Golden Gate Capital

One Embarcadero Center, 33rd
Floor
 San Francisco, CA 94111
	 	11,499 shares of Series B Preferred Stock	 	
			
	 CCG CI, LLC
 c/o Golden Gate Capital
 One Embarcadero Center, 33rd
Floor
 San Francisco, CA 94111
	 	19,879 shares of Series B Preferred Stock	 	
			
	 Jazz Investors, LLC
 c/o Beecken Petty & Company
Healthcare
 Equity Partners
 200 W. Madison Street, Suite
1910
 Chicago, IL 60606
	 	1,325,295 shares of Series B Preferred Stock	 	
			
	 Lehman Brothers HealthCare Venture
 Capital
L.P.
 399 Park Avenue
 New York, NY 10022
 Attention: Fred Steinberg
	 	165,661 shares of Series B Preferred Stock	 	
			
	 Lehman Brothers P. A. L.L.C.
 399 Park Avenue

New York, NY 10022
 Attention: Fred Steinberg
	 	317,076 shares of Series B Preferred Stock	 	
			
	 Lehman Brothers Partnership Account 2000/2001, L.P.
 399
Park Avenue
 New York, NY 10022
 Attention: Fred
Steinberg
	 	142,858 shares of Series B Preferred Stock	 	
			
	 Lehman Brothers Offshore Partnership
 Account 2000/2001,
L.P.
 399 Park Avenue
 New York, NY 10022
 Attention: Fred Steinberg
	 	37,050 shares of Series B Preferred Stock	 	
			
	 Prospect Venture Partners II, L.P.
 435 Tasso Street,
Suite 200
 Palo Alto, CA 94301
	 	 660,849 shares of Series A Preferred Stock
 554,801 shares of Series B Preferred Stock
	 	

					
	 Name and Address
	 	 Securities
	 	 
	 Prospect Associates II, L.P.
 435 Tasso Street, Suite
200
 Palo Alto, CA 94301
	 	 10,063 shares of Series A Preferred Stock
 8,448
shares of Series B Preferred Stock
	 	
			
	 Versant Venture Capital II, L.P.
 3000 Sand Hill
Road
 Building 4, Suite 210
 Menlo Park, CA 94025
	 	 652,693 shares of Series A Preferred Stock
 547,954 shares of Series B Preferred Stock
	 	
			
	 Versant Side Fund II, L.P.
 3000 Sand Hill
Road
 Building 4, Suite 210
 Menlo Park, CA 94025
	 	 5,833 shares of Series A Preferred Stock
 4,897
shares of Series B Preferred Stock
	 	
			
	 Versant Affiliates Fund II-A, L.P.
 3000 Sand Hill Road
Building 4, Suite 210
 Menlo Park, CA 94025
	 	 12,386 shares of Series A Preferred Stock
 10,398
shares of Series B Preferred Stock
	 	
			
	 BVCF IV, L.P.
 One North Wacker Drive, Suite
2200
 Chicago, IL 60606
	 	198,794 shares of Series B Preferred Stock	 	
			
	 Adams Street V, L.P.
 One North Wacker Drive, Suite
2200
 Chicago, IL 60606
	 	198,794 shares of Series B Preferred Stock	 	
			
	 Cardinal Fund I, L.P.
 201 Main Street, Suite
2415
 Fort Worth, TX 76102
 Attention: Ray Pinson
	 	 265,059 shares of Series B Preferred Stock
 Warrant to Purchase 7,857 shares of Series BB Preferred Stock
	 	
			
	 FW Jazz Pharma Investors, L.P.
 201 Main Street, Suite
3100
 Fort Worth, TX 76102
 Attention: John H.
Fant
	 	 132,529 shares of Series B Preferred Stock
 Warrant to Purchase 3,929 shares of Series BB Preferred Stock
	 	
			
	 EGS Private Healthcare Partnership II, L.P.
 105 Rowayton
Ave.
 Rowayton, CT 06853
	 	200,838 shares of Series B Preferred Stock	 	

					
	 Name and Address
	 	 Securities
	 	 
	 EGS Private Healthcare Investors II, L.P.
 105 Rowayton
Ave.
 Rowayton, CT 06853
	 	31,674 shares of Series B Preferred Stock	 	
			
	 EGS Private Healthcare Canadian
 Partners,
L.P.
 105 Rowayton Ave.
 Rowayton, CT 06853
	 	30,221 shares of Series B Preferred Stock	 	
			
	 EGS Private Healthcare Presidents Fund, L.P.
 105
Rowayton Ave.
 Rowayton, CT 06853
	 	2,324 shares of Series B Preferred Stock	 	
			
	 Samuel R. Saks
	 	 238,546 shares of Common Stock
 13,553 shares of
Series A Preferred Stock
 66,264 shares of Series B Preferred Stock
	 	
			
	 Bruce C. Cozadd
	 	 178,910 shares of Common Stock
 66,264 shares of
Series B Preferred Stock
	 	
			
	 Robert M. Myers
	 	 94,650 shares of Common Stock
 46,385 shares of
Series B Preferred Stock
	 	
			
	 Janne L.T. Wissel
	 	 29,818 shares of Common Stock
 66,264 shares of
Series B Preferred Stock
	 	
			
	 Matthew K. Fust
	 	 29,818 shares of Common Stock
 19,879 shares of
Series B Preferred Stock
	 	
			
	 Carol A. Gamble
	 	27,107 shares of Common Stock	 	
			
	 Waud Capital Partners, L.P.
 560 Oakwood Avenue, Suite
203
 Lake Forest, IL 60045
	 	477,106 shares of Series B Preferred Stock	 	

					
	 Name and Address
	 	 Securities
	 	 
	 Waud Capital Affiliates, L.L.C.
 560 Oakwood Avenue,
Suite 203
 Lake Forest, IL 60045
	 	53,011 shares of Series B Preferred Stock	 	
			
	 Deep Cove Mezzanine, LLC
 560 Oakwood Ave, Suite
203
 Lake Forest, IL 60045
	 	Warrants to purchase 49,108 shares of Series BB Preferred Stock	 	
			
	 Lerner Enterprises, LLP
 c/o Oak Hill Advisors
LP
 65 East 55th Street, 32nd Floor
 New York, NY
10022
	 	Warrants to purchase 6,472 shares of Series BB Preferred Stock	 	
			
	 LB I Group Inc.
 c/o Lehman Brothers
 399 Park Avenue, 9th Floor
 New York, NY 10022
	 	Warrants to purchase 304,469 shares of Series BB Preferred Stock	 	
			
	 KKR TRS Holdings, Inc.
 c/o KKR Financial
Corp.
 4 Embarcadero Center, Suite 2050
 San Francisco, CA
94111
	 	Warrants to purchase 245,540 shares of Series BB Preferred Stock	 	
			
	 General Electric Pension Trust
 c/o GE Asset Management
Incorporated
 3001 Summer Road
 P.O. Box 7900
 Stamford, CT 06904-7900
	 	Warrants to purchase 78,573 shares of Series BB Preferred Stock	 	
			
	 Coast DL Funding LLC
 c/o Oak Hill Advisors LP

65 East 55th Street, 32nd Floor
 New York, NY 10022
	 	Warrants to purchase 40,102 shares of Series BB Preferred Stock	 	
			
	 Oak Hill Credit Opportunities Financing, Ltd.
 c/o Oak
Hill Advisors LP
 65 East 55th Street, 32nd Floor
 New York, NY
10022
	 	Warrants to purchase 26,597 shares of Series BB Preferred Stock	 	

					
	 Name and Address
	 	 Securities
	 	 
	 Oak Hill Credit Alpha Finance I
 (Offshore),
Ltd.
 c/o Oak Hill Advisors LP
 65 East 55th Street, 32nd
Floor
 New York, NY 10022
	 	Warrants to purchase 17,453 shares of Series BB Preferred Stock	 	
			
	 Oak Hill Credit Alpha Finance I, LLC
 c/o Oak Hill
Advisors LP
 65 East 55th Street, 32nd Floor
 New York, NY
10022
	 	Warrants to purchase 5,628 shares of Series BB Preferred StockForm of Indemnification Agreement

 Exhibit 10.1 
 INDEMNIFICATION AGREEMENT 
 AGREEMENT, made this      day of
            , 2007, between Jazz Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and
                     (the “Indemnitee”). 
 W I T N E S S E T H: 
 WHEREAS, the Indemnitee is a director and/or officer of the Company.

 WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are
provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation. 
 WHEREAS, in recognition of Indemnitee’s need for substantial protection against personal liability in order to enhance Indemnitee’s continued
service to the Company in an effective manner and Indemnitee’s reliance on the provisions of the Company’s Certificate of Incorporation (“Certificate of Incorporation”) and the Company’s Bylaws (the “Bylaws”)
requiring indemnification of the Indemnitee to the fullest extent permitted by law, and in part to provide Indemnitee with specific contractual assurance that the protection promised by such Certificate of Incorporation and Bylaws will be available
to Indemnitee (regardless of, among other things, any amendment to or revocation of such Certificate of Incorporation or Bylaws or any change in the composition of the Company’s Board of Directors or acquisition transaction relating to the
Company), the Company wishes to provide in this Agreement for the indemnification of and the advancing of expenses to Indemnitee to the fullest extent (whether partial or complete) permitted by law and as set forth in this Agreement. 
 [WHEREAS, the Company and Indemnitee entered into an Indemnification Agreement dated
            , 2003 (the “Prior Indemnification Agreement”), at which time the Company was a California corporation.] 
 WHEREAS, the Company subsequently reincorporated in the State of Delaware. 
 WHEREAS, the Certificate of Incorporation, the Bylaws and the General Corporation Law of the State of Delaware (“DGCL”) expressly provide that
the indemnification provisions set forth therein are not exclusive and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification.

 WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on
behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified. 

 WHEREAS, this Agreement is a supplement to and in furtherance of the Certificate of Incorporation and
Bylaws and any resolutions adopted pursuant thereto and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. 
 WHEREAS, the Company and Indemnitee desire to supersede and replace the Prior Indemnification Agreement with this Agreement. 
 NOW, THEREFORE, in consideration of the premises and of Indemnitee agreeing to serve or continuing to serve the Company directly or, at its request, with another enterprise, and intending to be legally bound hereby,
the parties hereto agree as follows: 
 Section 1. Basis Indemnification Agreement. (a) In the event Indemnitee
was, is or becomes a party to or witness or other participant in, or is threatened to be made a party to or witness or other participant in, a Claim (as defined in Section 9(b) herein) by reason of (or arising in part out of) an Indemnifiable
Event (as defined in Section 9(d) herein), the Company shall indemnify Indemnitee (including its respective directors, officers, partners, members, employees and agents, as applicable) and each person who controls any of them or who may be
liable within the meaning of Section 15 the Securities Act of 1933, as amended (the “Securities Act”) or Section 20 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to the fullest extent
permitted by law as soon as practicable but in any event no later than 30 days after written demand is presented to the Company, against any and all Expenses (as defined in Section 9(c) herein), judgments, fines, penalties and amounts paid in
settlement (including all interest, assessments and other charges paid or payable in connection therewith) of such Claim actually and reasonably incurred by or on behalf of Indemnitee in connection with such Claim and any federal, state, local or
foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement. Subject to Section 6, if requested by Indemnitee in writing, the Company shall advance (within ten business days of such
written request) any and all Expenses to Indemnitee (an “Expense Advance”). Notwithstanding anything in this Agreement to the contrary, and except as provided in Section 3, Indemnitee shall not be entitled to indemnification or any
Expense Advance pursuant to this Agreement in connection with any Claim (i) initiated by Indemnitee against the Company or any director or officer of the Company unless the Company has joined in or consented to the initiation of such Claim or
such Claim relates to a matter described in Section 3, (ii) made on account of Indemnitee’s conduct which is determined by final judgment or other final adjudication to have constituted a breach of Indemnitee’s duty of loyalty to
the Company or its stockholders or an act or omission not in good faith or which involved intentional misconduct or a knowing violation of the law, (iii) if such indemnification or advancement of Expenses would cause the Company to act in
violation of applicable law or any undertaking appearing in and required by the rules and regulations promulgated under the Securities Act or any registration statement filed with the Securities and Exchange Commission (“SEC”) under the
Securities Act, or (iv) for which final judgment or adjudication is rendered against Indemnitee for an accounting, disgorgement or repayment of profits made from the purchase or sale by Indemnitee of securities of the Company against
Indemnitee, or in connection with a settlement by or on behalf of Indemnitee to the extent it is acknowledged by Indemnitee and the Company that such amount paid in settlement resulted from Indemnitee’s conduct from which Indemnitee received
monetary personal profit, pursuant to the provisions of Section 16(b) of the Exchange Act. 
  

 2 

 (b) Notwithstanding the foregoing, (i) the indemnification obligations of the Company under
Section 1(a) shall be subject to the condition that the Reviewing Party shall not have determined (in a written opinion, in any case in which the special independent counsel referred to in Section 2 hereof is involved) that Indemnitee
would not be permitted to be indemnified under applicable law or the terms of this Agreement, and (ii) the obligation of the Company to make an Expense Advance pursuant to Section 1(a) shall be subject to the condition that the Company
receives an undertaking that, if, when and to the extent that the Reviewing Party determines that Indemnitee would not be permitted to be so indemnified under applicable law, the Company shall be entitled to be reimbursed by Indemnitee (who hereby
agrees to reimburse the Company) for all such amounts theretofore paid; provided, however, that if Indemnitee has commenced legal proceedings in the Court of Chancery of the State of Delaware (the “Delaware Court”) to secure a
determination that Indemnitee should be indemnified under applicable law, any determination made by the Reviewing Party that Indemnitee would not be permitted to be indemnified under applicable law shall not be binding and Indemnitee shall not be
required to reimburse the Company for any Expense Advance until a final judicial determination is made with respect thereto (as to which all rights of appeal therefrom have been exhausted or lapsed). Indemnitee’s obligation to reimburse the
Company for Expense Advances shall be unsecured and no interest shall be charged thereon. If there has been no determination by the Reviewing Party or if the Reviewing Party determines that Indemnitee substantively would not be permitted to be
indemnified in whole or in part under applicable law or the terms of this Agreement, Indemnitee shall have the right to commence litigation in the Delaware Court seeking an initial determination by the court or challenging any such determination by
the Reviewing Party or any aspect thereof and the Company hereby consents to service of process and to appear in any such proceeding. Any determination by the Reviewing Party otherwise shall be conclusive and binding on the Company and Indemnitee.

 Section 2. Special Independent Counsel. The Company agrees that if there is a Change in Control of the Company
(other than a Change in Control which has been approved by two- thirds or more of the Company’s Board of Directors who were directors immediately prior to such Change in Control) then with respect to all matters thereafter arising concerning
the rights of Indemnitee to indemnity payments and Expense Advances under this Agreement or any other agreement, the Bylaws or Certificate of Incorporation now or hereafter in effect relating to Claims for Indemnifiable Events, the Company shall
seek legal advice only from special independent counsel selected by Indemnitee and approved by the Company (which approval shall not be unreasonably withheld or delayed) and who has not otherwise performed services for the Company or for Indemnitee
within the last five years (other than in connection with such matters). In the event that Indemnitee and the Company are unable to agree on the selection of the special independent counsel, such special independent counsel shall be selected by lot
from among at least five law firms with offices in the State of Delaware having more than fifty attorneys, having a rating of “av” or better in the then current Martindale Hubbell Law Directory and having attorneys which specialize in
corporate law. Such selection shall be made in the presence of Indemnitee (and his legal counsel or either of them, as Indemnitee may elect). Such counsel, among other things, shall, within 90 days of its retention, render its written opinion to

  

 3 

 
the Company and Indemnitee as to whether and to what extent Indemnitee would be permitted to be indemnified under applicable law. The Company agrees to pay
the reasonable fees of the special independent counsel referred to above and to fully indemnify such counsel against any and all expenses (including attorneys’ fees), claims, liabilities, and damages arising out of or relating to this Agreement
or its engagement pursuant hereto. 
 Section 3. Indemnification for Additional Expenses. The Company shall indemnify
Indemnitee against any and all Expenses and, if requested by Indemnitee in writing, shall (within ten business days of such written request) advance such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any Claim asserted
against or action brought by Indemnitee for (i) indemnification or advance payment of Expenses by the Company under this Agreement or any other agreement, the Bylaws or Certificate of Incorporation now or hereafter in effect relating to Claims
for Indemnifiable Events and/or (ii) recovery under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification,
advance expense payment or insurance recovery, as the case may be. The Indemnitee shall qualify for advances solely upon the execution and delivery to the Company of an undertaking providing that the Indemnitee undertakes to repay the advance to the
extent that it is ultimately determined by final judgment or adjudication of a court of appropriate jurisdiction that the Indemnitee is not entitled to be indemnified by the Company. 
 Section 4. Partial Indemnity, Etc. If Indemnitee is entitled under any provisions of this Agreement to indemnification by the
Company of some or a portion of the Expenses, liabilities, judgments, fines, penalties and amounts paid in settlement of a Claim but not, however, for all of the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the
portion thereof to which Indemnitee is entitled. Moreover, notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been successful on the merits or otherwise in defense of any or all Claims relating in whole or in
part to an Indemnifiable Event or in defense of any issue or matter therein, including dismissal without prejudice, Indemnitee shall be indemnified against all Expenses incurred in connection therewith. In connection with any determination by the
Reviewing Party or otherwise as to whether Indemnitee is entitled to be indemnified hereunder the burden of proof shall be on the Company to establish that Indemnitee is not so entitled. 
 Section 5. No Presumption. For purposes of this Agreement, the termination of any action, suit or proceeding by judgment, order,
settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent, shall not create a presumption that Indemnitee did not meet any particular standard of conduct or have any particular belief.
Any determination by the Reviewing Party that indemnitee is not entitled to indemnification hereunder shall not be a defense by the Company to any Claim by Indemnitee to enforce any right to indemnification or advancement of Expenses pursuant to
this Agreement or any other agreement, the Bylaws or Certificate of Incorporation now or hereafter in effect. 
 Section 6.
Notification and Defense of Claim. Within 30 days after receipt by Indemnitee of notice of the commencement of a Claim which may involve an Indemnifiable Event, Indemnitee will, if a claim in respect thereof is to be made against the
Company under 

  

 4 

 
this Agreement, submit to the Company a written notice identifying the proceeding, but the omission so to notify the Company will not relieve it from any
liability which it may have to Indemnitee under this Agreement unless the Company is materially prejudiced by such lack of notice. With respect to any such Claim as to which Indemnitee notifies the Company of the commencement thereof: 
 (a) the Company will be entitled to participate therein at its own expense; 
 (b) except as otherwise provided below, to the extent that it may wish, the Company jointly with any other indemnifying party similarly notified will be entitled to assume the defense thereof, with counsel
satisfactory to Indemnitee. After notice from the Company to Indemnitee of its election to assume the defense thereof, the Company will not be liable to Indemnitee under this Agreement for any legal or other expenses subsequently incurred by
Indemnitee in connection with the defense thereof other than reasonable costs of investigation or as otherwise provided below. Indemnitee shall have the right to employ its own counsel in such action, suit or proceeding, but the fees and expenses of
such counsel incurred after notice from the Company of its assumption of the defense thereof shall be at the expense of Indemnitee unless (i) the employment of counsel by Indemnitee has been authorized by the Company, (ii) Indemnitee shall
have reasonably concluded that there may be a conflict of interest between the Company and the Indemnitee in the conduct of the defense of such action, or (iii) the Company shall not in fact have employed counsel to assume the defense of such
action, in each of which cases the fees and expenses of counsel shall be at the expense of the Company. The Company shall not be entitled to assume the defense of any claim brought by or on behalf of the Company or as to which Indemnitee shall have
made the conclusion provided for in clause (ii) above; and 
 (c) the Company shall not be liable to indemnify Indemnitee under this
Agreement for any amounts paid in settlement of any action or claim effected without its written consent. The Company shall not settle any action or claim in any manner which would impose any penalty or limitation on Indemnitee without
Indemnitee’s written consent. Neither the Company nor Indemnitee will unreasonably withhold or delay their consent to any proposed settlement. 
 Section 7. Non-exclusivity, Etc. The rights of Indemnitee hereunder shall be in addition to any other rights Indemnitee may have under the Certificate of Incorporation, the Bylaws, the DGCL, any agreement, a vote of
the stockholders, a resolution of directors or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted
by such Indemnitee acting on behalf of the Company and at the request of the Company prior to such amendment, alteration or repeal. To the extent that a change in the DGCL (whether by statute or judicial decision), the Certificate of Incorporation
or the Bylaws permits greater indemnification by agreement than would be afforded currently under the Certificate of Incorporation, the Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement
the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy

  

 5 

 
given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise,
shall not prevent the concurrent assertion or employment of any other right or remedy. Notwithstanding anything to the contrary herein, the indemnification provided under this agreement shall continue as to the Indemnitee for any action the
Indemnitee took or did not take while serving in an indemnified capacity even though the Indemnitee may have ceased to serve in such capacity. 
 Section 8. Liability Insurance. To the extent the Company maintains an insurance policy or policies providing directors’ and officers’ liability insurance, Indemnitee shall be covered by such policy or
policies in accordance with its or their terms to the maximum extent of the coverage available for any Company director or officer. If, at the time the Company receives notice from any source of a Claim as to which Indemnitee is a party or a
participant (as a witness or otherwise), the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective
policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Claim in accordance with the terms of such policies. 
 Section 9. Certain Definitions. 
 (a) Change in Control: shall be deemed to have occurred if: 
 (i) any person, as that term is used in Section 13(d) and
Section 14(d)(2) of the Exchange Act, becomes, is discovered to be, or files a report on Schedule 13D or 14D-1 (or any successor schedule, form or report) disclosing that such person is a beneficial owner (as defined in Rule 13d-3
under the Exchange Act or any successor rule or regulation), directly or indirectly, of securities of the Company representing 20% or more of the total voting power of the Company’s then outstanding Voting Securities (unless such person becomes
such a beneficial owner in connection with the initial public offering of the Company); 
 (ii) individuals who, as of the consummation date
of the Company’s initial public offering, constitute the Board of Directors of the Company cease for any reason to constitute at least a majority of the Board of Directors of the Company, unless any such change is approved by a unanimous vote
of the members of the Board of Directors of the Company in office immediately prior to such cessation; 
 (iii) the Company, or any material
subsidiary of the Company, is merged, consolidated or reorganized into or with an Acquiring Person or securities of the Company are exchanged for securities of an Acquiring Person, and immediately after such merger, consolidation, reorganization or
exchange less than a majority of 

  

 6 

 
the combined voting power of the then outstanding securities of the Acquiring Person immediately after such transaction are held, directly or indirectly, in
the aggregate by the holders of Voting Securities immediately prior to such transaction; 
 (iv) the Company, or any material subsidiary of
the Company, in any transaction or series of related transactions, sells or otherwise transfers all or substantially all of its assets to an Acquiring Person, and less than a majority of the combined voting power of the then outstanding securities
of the Acquiring Person immediately after such sale or transfer is held, directly or indirectly, in the aggregate by the holders of Voting Securities immediately prior to such sale or transfer; 
 (v) the Company and its subsidiaries, in any transaction or series of related transactions, sells or otherwise transfers business operations that
generated two thirds or more of the consolidated revenues (determined on the basis of the Company’s four most recently completed fiscal quarters) of the Company and its subsidiaries immediately prior thereto; 
 (vi) the Company files a report or proxy statement with the Securities and Exchange Commission pursuant to the Exchange Act disclosing that a change in
control of the Company has or may have occurred or will or may occur in the future pursuant to any then existing contract or transaction; or 
 (vii) any other transaction or series of related transactions occur that have substantially the effect of the transactions specified in any of the preceding clauses in this Section 9(a). 
 Notwithstanding the provisions of Section 9(a)(i) or 9(a)(iv), unless otherwise determined in a specific case by majority vote of the Board of
Directors of the Company, a Change of Control shall not be deemed to have occurred for purposes of this Agreement solely because (i) the Company, (ii) an entity in which the Company directly or indirectly beneficially owns 50% or more of
the voting securities or (iii) any Company sponsored employee stock ownership plan, or any other employee benefit plan of the Company, either files or becomes obligated to file a report or a proxy statement under or in response to
Schedule 13D, Schedule 14D-1, Form 8-K or Schedule 14A (or any successor schedule, form or report or item therein) under the Exchange Act, disclosing beneficial ownership by it of shares of stock of the Company, or because the
Company reports that a Change in Control of the Company has or may have occurred or will or may occur in the future by reason of such beneficial ownership. 
 (b) Claim: any threatened, pending or completed action, suit, proceeding or alternative dispute resolution mechanism, or any inquiry, hearing or investigation whether conducted by the Company or any other party,
whether civil, criminal, administrative, investigative or other. 
  

 7 

 (c) Expenses: include attorneys’ fees and all other costs, fees, expenses and obligations of
any nature whatsoever paid or incurred in connection with investigating, defending, being a witness in or participating in (including appeal), or preparing to defend, be a witness in or participate in any Claim relating to any Indemnifiable Event or
to enforce Indemnitee’s rights to indemnification or advancement of Expenses pursuant to this Agreement or any other agreement, the Bylaws or Certificate of Incorporation now or hereafter in effect. 
 (d) Indemnifiable Event: any event or occurrence (whether before or after the date hereof) related to the fact that Indemnitee is or was a director,
officer, employee, consultant, agent or fiduciary of or to the Company, or is or was serving at the request of the Board of Directors as a director, officer, employee, trustee, agent or fiduciary of another corporation, partnership, joint venture,
employee benefit plan, trust or other enterprise, or by reason of anything done or not done by Indemnitee in any such capacity including, without limitation, any claim or investigation under the Securities Act, the Exchange Act or other federal or
state statutory law or regulation, at common law or otherwise on which relate directly to indirectly to the registration, purchase, sale or ownership of any securities of the Company or to any fiduciary obligation owed with respect thereto or as a
direct or indirect result of any claim made by any stockholder of the Company against Indemnitee and arising out of or related to any round of financing of the Company (including but not limited to claims regarding non-participation, or non-pro rata
participation, in such round by such stockholder), or made by a third party against Indemnitee based on any misstatement or omission of a material fact by the Company in violation of any duty of disclosure imposed on the Company by federal or state
securities or common laws. 
 (e) Reviewing Party: (i) the Company’s Board of Directors (provided that a majority of directors
are not parties to the particular Claim for which Indemnitee is seeking indemnification) or (ii) any other person or body appointed by the Company’s Board of Directors, who is not a party to the particular Claim for which Indemnitee is
seeking indemnification, or (iii) if there has been a Change in Control (other than a Change of Control which has been approved by two-thirds or more of the Company’s Board of Directors who were directors immediately prior to such Change
of Control), the special independent counsel referred to in Section 2 hereof. 
 (f) Voting Securities: any securities of the
Company which vote generally in the election of directors. 
 Section 10. Amendments, Termination and Waiver. No
supplement, modification, amendment or termination of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any
other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. 
  

 8 

 Section 11. Subrogation. In the event of payment under this Agreement, the
Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such
documents necessary to enable the Company effectively to bring suit to enforce such rights. 
 Section 12. No Duplication of
Payments. The Company shall not be liable under this Agreement to make any payment in connection with any Claim made against Indemnitee to the extent Indemnitee has otherwise actually received payment (under insurance policy, Certificate of
Incorporation or otherwise) of the amounts otherwise indemnifiable hereunder. 
 Section 13. Securities Act Liabilities.
Indemnitee acknowledges that paragraph (h) of Item 512 of Regulation S-K currently generally requires the Company to undertake in connection with any registration statement filed under the Act to submit the issue of the enforceability of
Indemnitee’s rights under this Agreement in connection with any liability under the Act on public policy grounds to a court of appropriate jurisdiction and to be governed by any final adjudication of such issue. Indemnitee specifically agrees
that any such undertaking shall supersede the provisions of this Agreement and to be bound by any such undertaking. 
 Section 14. Binding Effect, Etc. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors, assigns, including any direct or indirect
successor by purchase, merger, consolidation or otherwise to all or substantially all of the business and/or assets of the Company, spouse, heirs, and personal and legal representatives. This Agreement shall continue in effect regardless of whether
Indemnitee continues to serve as a director or officer (or in one of the capacities enumerated in Section 9(d) hereof) of the Company or of any other enterprise at the Board of Director’s request. The Company shall require any successor
(whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company, expressly to assume and agree to perform this Agreement in the same manner and to the same extent
that the Company would be required to perform if no such succession had taken place. 
 Section 15. Limitations on
Actions. No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company against an Indemnitee or an Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives after the
expiration of three (3) years from the date of accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such
three-year period; provided, however, that if any shorter period of limitations is otherwise applicable to such cause of action, such shorter period shall govern. 
 Section 16. Severability. The provisions of this Agreement shall be severable in the event that any of the provisions hereof (including any provision within a single section, paragraph or
sentence) are held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable, and the remaining provisions shall remain enforceable to the fullest extent permitted by law. 
  

 9 

 Section 17. Applicable Law and Consent to Jurisdiction. This Agreement and the legal
relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and unconditionally
(i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court and not in any other state or federal court in the United States of America or any court in any other
country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, irrevocably, to the extent such party is not a
resident of the State of Delaware, National Corporate Research, Ltd., 615 South Dupont Highway, City of Dover, County of Kent, Delaware 19901 as its agent in the State of Delaware as such party’s agent for acceptance of legal process in
connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or
proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum. 
 Section 18. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes
be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

 Section 19. Entire Agreement. This Agreement constitutes the entire agreement between the parties regarding the subject
matter hereof and supersedes and replaces any and all prior negotiations, correspondence, understandings and agreements, including without limitation the Prior Indemnification Agreement, between the parties regarding the subject matter hereof.

  

 10 

 Executed this      day of
            , 2007. 
  

			
	 Jazz Pharmaceuticals, Inc.

		
	 By:
	 	  

	 Its:
	 	
	
	 [Indemnitee]

	
	  

  

 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]